SUPPLEMENT

Q2 2020 — Financial disclosures

Q2 2020PDF · 12 pages1.0 MB
Merck & Co., Inc.
Financial Highlights Package
Second Quarter 2020
Table of Contents
Table 1: 	GAAP P&L..........................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2
Table 2a: GAAP to Non-GAAP Reconciliation 2Q20.........................3
Table 2b: GAAP to Non-GAAP Reconciliation June YTD 20.............4
Table 2c: GAAP to Non-GAAP Reconciliation 2Q19.........................5
Table 2d: GAAP to Non-GAAP Reconciliation June YTD 19 ............6
Table 3: Sales – Current Year and Prior Year by Quarter ...............7
Table 3a: Sales – U.S. / Ex- U.S. 2Q20.............................................8
Table 3b: Sales – U.S. / Ex- U.S. June YTD 20 ...............................9
Table 3c: Sales – Pharmaceutical Geographic Split .......................10
Table 4: Other (Income) Expense .................................................11

-- 1 of 12 --

Sales 	10,872	$ 	11,760	$ 	-8% 	22,929	$ 	22,575	$ 	2%
Costs, Expenses and Other
Cost of sales (1) 3,159 	3,401 	-7% 	6,471 	6,453 	0%
Selling, general and administrative (1) 2,378 	2,712 	-12% 	4,933 	5,138 	-4%
Research and development (1) 2,123 	2,189 	-3% 	4,331 	4,119 	5%
Restructuring costs (2) 83 	59 	41% 	155 	212 	-27%
Other (income) expense, net (1) (390) 	140 	* 	(318) 	327 	*
Income Before Taxes 	3,519 	3,259 	8% 	7,357 	6,326 	16%
Taxes on Income (1) 509 	615 	1,128 	820
Net Income 	3,010 	2,644 	14% 	6,229 	5,506 	13%
Less: Net Income (Loss) Attributable to Noncontrolling Interests (1) 8 	(26) 	8 	(79)
Net Income Attributable to Merck & Co., Inc. 	3,002	$ 	2,670	$ 	12% 	6,221	$ 	5,585	$ 	11%
Earnings per Common Share Assuming Dilution 	1.18	$ 	1.03	$ 	15% 	2.45	$ 	2.15	$ 	14%
Average Shares Outstanding Assuming Dilution 	2,536 	2,588 	2,542 	2,596
Tax Rate (3) 14.5% 	18.9% 	15.3% 	13.0%
* 100% or greater
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
(3) The effective income tax rate for the first six months of 2019 reflects a net tax benefit of $360 million related to the settlement of certain federal income tax matters.
(2) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.
GAAP
% ChangeJune YTD
2020
June YTD
2019
2Q19	2Q20
GAAP
% Change
(1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See accompanying tables for details.
1

-- 2 of 12 --

. 	.
Sales 	12,057	$ 	10,872	$ 	22,929	$ 	10,816	$ 	11,760	$ 	22,575	$ 	12,397	$ 	11,868	$ 	46,840	$ 	-8% 	2%
Costs, Expenses and Other
Cost of sales 	3,312 	3,159 	6,471 	3,052 	3,401 	6,453 	3,990 	3,669 	14,112 	-7% 	0%
Selling, general and administrative 	2,555 	2,378 	4,933 	2,425 	2,712 	5,138 	2,589 	2,888 	10,615 	-12% 	-4%
Research and development 	2,209 	2,123 	4,331 	1,931 	2,189 	4,119 	3,204 	2,548 	9,872 	-3% 	5%
Restructuring costs 	72 	83 	155 	153 	59 	212 	232 	194 	638 	41% 	-27%
Other (income) expense, net 	71 	(390) 	(318) 	188 	140 	327 	35 	(223) 	139 	* 	*
Income Before Taxes 	3,838 	3,519 	7,357 	3,067 	3,259 	6,326 	2,347 	2,792 	11,464 	8% 	16%
Taxes on Income 	619 	509 	1,128 	205 	615 	820 	440 	428 	1,687
Net Income 	3,219 	3,010 	6,229 	2,862 	2,644 	5,506 	1,907 	2,364 	9,777 	14% 	13%
Less: Net Income (Loss) Attributable to Noncontrolling Interests 	- 	8 	8 	(53) 	(26) 	(79) 	6 	7 	(66)
Net Income Attributable to Merck & Co., Inc. 	3,219	$ 	3,002	$ 	6,221	$ 	2,915	$ 	2,670	$ 	5,585	$ 	1,901	$ 	2,357	$ 	9,843	$ 	12% 	11%
Earnings per Common Share Assuming Dilution 	1.26	$ 	1.18	$ 	2.45	$ 	1.12	$ 	1.03	$ 	2.15	$ 	0.74	$ 	0.92	$ 	3.81	$ 	15% 	14%
Average Shares Outstanding Assuming Dilution 	2,547 	2,536 	2,542 	2,603 	2,588 	2,596 	2,572 	2,559 	2,580
Tax Rate 	16.1% 	14.5% 	15.3% 	6.7% 	18.9% 	13.0% 	18.7% 	15.3% 	14.7%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
2Q 	3Q 	4Q 	Full Year 	2Q 	June YTD	1Q 	2Q 	June YTD 	1Q 	June YTD
2020 	2019 	% Change
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1a
2

-- 3 of 12 --

Cost of sales 	3,159	$ 	282 	25 	307 	2,852	$
Selling, general and administrative 	2,378 	163 	11 	174 	2,204
Research and development 	2,123 	(65) 	31 	(34) 	2,157
Restructuring costs 	83 	83 	83 	-
Other (income) expense, net 	(390) 	63 	(16) 	47 	(437)
Income Before Taxes 	3,519 	(443) 	(150) 	16 	(577) 	4,096
Income Tax Provision (Benefit) 	509 	(73) (3) (27) (3) 5 (3) (95) 	604
Net Income 	3,010 	(370) 	(123) 	11 	(482) 	3,492
Less: Net Income Attributable to Noncontrolling
Interests 8 	- 	8
Net Income Attributable to Merck & Co., Inc. 	3,002 	(370) 	(123) 	11 	(482) 	3,484
Earnings per Common Share Assuming Dilution 	1.18	$ 	(0.14) 	(0.05) 	- 	(0.19) 	1.37	$
Tax Rate 	14.5% 	14.7%
Only the line items that are affected by non-GAAP adjustments are shown.
Table 2a
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Certain Other
Items
Adjustment
Subtotal
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets recognized as a result of business acquisitions. Amounts included in selling, general and
administrative expenses reflect $119 million of expenses related to the company's planned spin-off of Organon & Co., and other acquisition and divestiture-related costs. Amounts included in
research and development expenses primarily reflect a reduction in expenses related to a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts
included in other (income) expense, net, primarily reflect an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-
Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
SECOND QUARTER 2020
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
3

-- 4 of 12 --

Cost of sales 	6,471	$ 	578 	93 	671 	5,800	$
Selling, general and administrative 	4,933 	441 	22 	463 	4,470
Research and development 	4,331 	(28) 	48 	20 	4,311
Restructuring costs 	155 	155 	155 	-
Other (income) expense, net 	(318) 	52 	(16) 	36 	(354)
Income Before Taxes 	7,357 	(1,043) 	(318) 	16 	(1,345) 	8,702
Income Tax Provision (Benefit) 	1,128 	(231) (3) (34) (3) 5 (3) (260) 	1,388
Net Income 	6,229 	(812) 	(284) 	11 	(1,085) 	7,314
Less: Net Income Attributable to Noncontrolling
Interests 8 	- 	8
Net Income Attributable to Merck & Co., Inc. 	6,221 	(812) 	(284) 	11 	(1,085) 	7,306
Earnings per Common Share Assuming Dilution 	2.45	$ 	(0.32) 	(0.10) 	- 	(0.42) 	2.87	$
Tax Rate 	15.3% 	16.0%
Only the line items that are affected by non-GAAP adjustments are shown.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets recognized as a result of business acquisitions. Amounts included in selling, general and
administrative expenses reflect $284 million of expenses related to the company's planned spin-off of Organon & Co., approximately $95 million of costs related to the acquisition of ArQule,
Inc., and other acquisition and divestiture-related costs. Amounts included in research and development expenses primarily reflect a reduction in expenses related to a decrease in the
estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income) expense, net, primarily reflect an increase in the estimated fair value
measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture, partially offset by royalty income.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
SIX MONTHS ENDED JUNE 30, 2020
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Certain Other
Items
Adjustment
Subtotal
4

-- 5 of 12 --

Cost of sales 	3,401	$ 	447 	65 	512 	2,889	$
Selling, general and administrative 	2,712 	61 	32 	93 	2,619
Research and development 	2,189 	4 	3 	7 	2,182
Restructuring costs 	59 	59 	59 	-
Other (income) expense, net 	140 	148 	48 	196 	(56)
Income Before Taxes 	3,259 	(660) 	(159) 	(48) 	(867) 	4,126
Income Tax Provision (Benefit) 	615 	(109) (3) (25) (3) (11) (3) (145) 	760
Net Income 	2,644 	(551) 	(134) 	(37) 	(722) 	3,366
Less: Net (Loss) Income Attributable to
Noncontrolling Interests (26) 	(36) 	(36) 	10
Net Income Attributable to Merck & Co., Inc. 	2,670 	(515) 	(134) 	(37) 	(686) 	3,356
Earnings per Common Share Assuming Dilution 	1.03	$ 	(0.20) 	(0.05) 	(0.02) 	(0.27) 	1.30	$
Tax Rate 	18.9% 	18.4%
Only the line items that are affected by non-GAAP adjustments are shown.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
(1) Amount included in cost of sales primarily reflects $373 million of expenses for the amortization of intangible assets recognized as a result of business acquisitions, as well as $69 million of
intangible asset impairment charges. Amount included in selling, general and administrative expenses primarily reflects integration, transaction and certain other costs related to business
acquisitions and divestitures, including costs related to the acquisition of Antelliq Corporation. Amount included in other (income) expense, net primarily reflects goodwill impairment charges
related to certain businesses in the Healthcare Services segment and expenses related to an increase in the estimated fair value of liabilities for contingent consideration related to the
termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Certain Other
Items
Adjustment
Subtotal Non-GAAP
Table 2c
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
SECOND QUARTER 2019
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
5

-- 6 of 12 --

Cost of sales 	6,453	$ 	860 	99 	959 	5,494	$
Selling, general and administrative 	5,138 	60 	32 	92 	5,046
Research and development 	4,119 	(27) 	3 	(24) 	4,143
Restructuring costs 	212 	212 	212 	-
Other (income) expense, net 	327 	315 	48 	363 	(36)
Income Before Taxes 	6,326 	(1,208) 	(346) 	(48) 	(1,602) 	7,928
Income Tax Provision (Benefit) 	820 	(207) (3) (56) (3) (304) (4) (567) 	1,387
Net Income 	5,506 	(1,001) 	(290) 	256 	(1,035) 	6,541
Less: Net (Loss) Income Attributable to
Noncontrolling Interests (79) 	(89) 	(89) 	10
Net Income Attributable to Merck & Co., Inc. 	5,585 	(912) 	(290) 	256 	(946) 	6,531
Earnings per Common Share Assuming Dilution 	2.15	$ 	(0.36) 	(0.11) 	0.10 	(0.37) 	2.52	$
Tax Rate 	13.0% 	17.5%
Only the line items that are affected by non-GAAP adjustments are shown.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
(1) Amount included in cost of sales primarily reflects $771 million of expenses for the amortization of intangible assets recognized as a result of business acquisitions, as well as $81 million of
intangible asset impairment charges. Amount included in selling, general and administrative expenses primarily reflects integration, transaction and certain other costs related to business
acquisitions and divestitures, including costs related to the acquisition of Antelliq Corporation. Amount included in research and development expenses primarily reflects a reduction in expenses
related to a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amount included in other (income) expense, net, primarily reflects goodwill and
intangible asset impairment charges related to certain businesses in the Healthcare Services segment and expenses related to an increase in the estimated fair value measurement of liabilities
for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Also includes a $360 million net
tax benefit related to the settlement of certain federal income tax matters and a $67 million tax charge related to the finalization of treasury regulations associated with the 2017 enactment of
U.S. tax legislation.
Non-GAAP
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
SIX MONTHS ENDED JUNE 30, 2019
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2d
GAAP
Acquisition and
Divestiture-Related
Costs (1)
Restructuring
Costs (2)
Certain Other
Items
Adjustment
Subtotal
6

-- 7 of 12 --

1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) $12,057 	$10,872 	$22,929 	$10,816 	$11,760 	$22,575 	$12,397 	$11,868 	$46,840 	-8 	-5 	2 	4
PHARMACEUTICAL 	10,655 	9,679 	20,334 	9,663 	10,460 	20,123 	11,095 	10,533 	41,751 	-7 	-6 	1 	3
Oncology
Keytruda 	3,284 	3,388 	6,672 	2,269 	2,634 	4,903 	3,070 	3,111 	11,084 	29 	31 	36 	38
Alliance Revenue – Lynparza (2) 145 	178 	323 	79 	111 	190 	123 	132 	444 	61 	62 	70 	72
Alliance Revenue – Lenvima (2) 128 	151 	279 	74 	97 	171 	109 	124 	404 	57 	57 	63 	64
Emend 	43 	33 	76 	117 	121 	237 	98 	53 	388 	-72 	-71 	-68 	-67
Vaccines (3)
Gardasil / Gardasil 9 	1,097 	656 	1,753 	838 	886 	1,724 	1,320 	693 	3,737 	-26 	-24 	2 	4
ProQuad / M-M-R II / Varivax 	435 	378 	813 	496 	675 	1,171 	623 	481 	2,275 	-44 	-43 	-31 	-30
RotaTeq 	222 	168 	391 	211 	172 	383 	180 	227 	791 	-2 	-1 	2 	3
Pneumovax 23 	256 	117 	373 	185 	170 	355 	237 	334 	926 	-31 	-29 	5 	7
Vaqta 	60 	28 	88 	47 	58 	105 	62 	71 	238 	-52 	-51 	-17 	-14
Hospital Acute Care
Bridion 	299 	224 	524 	255 	278 	533 	284 	313 	1,131 	-19 	-18 	-2
Noxafil 	94 	73 	168 	190 	193 	383 	177 	103 	662 	-62 	-60 	-56 	-55
Prevymis 	60 	63 	123 	32 	38 	70 	45 	50 	165 	66 	67 	76 	78
Primaxin 	51 	64 	115 	59 	71 	130 	77 	67 	273 	-10 	-6 	-11 	-8
Invanz 	64 	43 	108 	72 	78 	150 	57 	57 	263 	-45 	-39 	-28 	-24
Cancidas 	55 	43 	98 	61 	67 	129 	62 	58 	249 	-36 	-33 	-23 	-21
Cubicin 	46 	32 	78 	88 	67 	155 	52 	50 	257 	-53 	-51 	-50 	-48
Zerbaxa 	37 	32 	69 	26 	27 	53 	35 	32 	121 	19 	23 	30 	33
Immunology
Simponi 	215 	191 	406 	208 	214 	422 	203 	205 	830 	-11 	-8 	-4 	-1
Remicade 	88 	73 	160 	123 	98 	221 	101 	89 	411 	-26 	-25 	-28 	-26
Neuroscience
Belsomra 	79 	84 	163 	67 	76 	143 	80 	83 	306 	10 	8 	14 	13
Virology
Isentress / Isentress HD 	245 	196 	441 	255 	247 	502 	250 	223 	975 	-21 	-17 	-12 	-9
Zepatier 	55 	39 	94 	114 	108 	221 	83 	66 	370 	-63 	-62 	-57 	-56
Cardiovascular
Zetia 	145 	137 	282 	140 	156 	296 	147 	146 	590 	-12 	-12 	-5 	-4
Vytorin 	53 	39 	92 	97 	76 	174 	57 	54 	285 	-49 	-46 	-47 	-45
Atozet 	122 	115 	238 	94 	92 	186 	97 	108 	391 	25 	28 	28 	31
Alliance Revenue - Adempas (4) 53 	79 	133 	42 	51 	94 	50 	60 	204 	54 	54 	41 	41
Adempas (5) 56 	57 	113 	48 	53 	100 	57 	57 	215 	8 	9 	12 	14
Diabetes (6)
Januvia 	774 	854 	1,628 	824 	908 	1,732 	807 	943 	3,482 	-6 	-5 	-6 	-5
Janumet 	503 	490 	993 	530 	533 	1,063 	503 	475 	2,041 	-8 	-5 	-7 	-4
Women's Health
Implanon / Nexplanon 	195 	132 	326 	199 	183 	382 	199 	206 	787 	-28 	-26 	-15 	-13
NuvaRing 	63 	63 	126 	219 	240 	459 	241 	179 	879 	-74 	-73 	-73 	-72
Diversified Brands
Singulair 	155 	100 	255 	191 	160 	352 	152 	195 	698 	-38 	-37 	-27 	-26
Cozaar / Hyzaar 	102 	98 	200 	103 	109 	213 	116 	113 	442 	-10 	-7 	-6 	-3
Arcoxia 	70 	65 	135 	75 	75 	149 	72 	67 	288 	-13 	-9 	-9 	-7
Nasonex 	71 	49 	120 	96 	72 	168 	58 	67 	293 	-32 	-28 	-29 	-26
Follistim AQ 	41 	44 	85 	57 	63 	121 	62 	58 	241 	-31 	-30 	-29 	-28
Other Pharmaceutical (7) 1,194 	1,103 	2,293 	1,082 	1,203 	2,283 	1,149 	1,183 	4,615 	-8 	-6 	2
ANIMAL HEALTH 	1,214 	1,101 	2,314 	1,025 	1,124 	2,149 	1,122 	1,122 	4,393 	-2 	3 	8 	12
Livestock 	739 	648 	1,386 	611 	671 	1,282 	726 	777 	2,784 	-3 	3 	8 	13
Companion Animals 	475 	453 	928 	414 	453 	867 	396 	345 	1,609 	3 	7 	9
Other Revenues (8) 188 	92 	281 	128 	176 	303 	180 	213 	696 	-47 	-23 	-8
(6) Total Diabetes sales were $1,353 million and $1,418 million in the first and second quarters of 2020 and $1,402 million, $1,480 million, $1,360 million and $1,472 million for the
first, second, third and fourth quarters of 2019, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of Healthcare Services segment revenues, third-party manufacturing sales and miscellaneous corporate revenues, including revenue
hedging activities.
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Total Vaccines sales were $2,155 million and $1,418 million in the first and second quarters of 2020 and $1,887 million, $2,037 million, $2,517 million and $1,928 million for the
first, second, third and fourth quarters of 2019, respectively.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2020 	2019 	2Q 	June YTD
7

-- 8 of 12 --

2Q 2020 	2Q 2019 	% Change 	2Q 2020 	2Q 2019 	% Change 	2Q 2020 	2Q 2019 	% Change
TOTAL SALES (1) $10,872 	$11,760 	-8 	$4,634 	$5,193 	-11 	$6,238 	$6,567 	-5
PHARMACEUTICAL 	9,679 	10,460 	-7 	4,270 	4,807 	-11 	5,409 	5,653 	-4
Oncology
Keytruda 	3,388 	2,634 	29 	2,043 	1,498 	36 	1,345 	1,136 	18
Alliance Revenue - Lynparza (2) 178 	111 	61 	105 	66 	60 	73 	45 	61
Alliance Revenue - Lenvima (2) 151 	97 	57 	98 	54 	83 	53 	43 	23
Emend 	33 	121 	-72 	6 	67 	-91 	27 	54 	-49
Vaccines (3)
Gardasil / Gardasil 9 	656 	886 	-26 	168 	456 	-63 	488 	430 	13
ProQuad / M-M-R II / Varivax 	378 	675 	-44 	263 	500 	-47 	115 	174 	-34
RotaTeq 	168 	172 	-2 	100 	104 	-3 	68 	68
Pneumovax 23 	117 	170 	-31 	21 	123 	-83 	96 	47 	103
Vaqta 	28 	58 	-52 	17 	38 	-56 	11 	20 	-45
Hospital Acute Care
Bridion 	224 	278 	-19 	107 	129 	-17 	117 	149 	-21
Noxafil 	73 	193 	-62 	6 	100 	-94 	67 	93 	-27
Primaxin 	64 	71 	-10 	1 	81 	63 	70 	-10
Prevymis 	63 	38 	66 	28 	19 	46 	35 	18 	89
Cancidas 	43 	67 	-36 	(2) 	3 	-164 	45 	64 	-30
Invanz 	43 	78 	-45 	18 	-99 	43 	60 	-29
Zerbaxa 	32 	27 	19 	17 	13 	30 	15 	14 	10
Cubicin 	32 	67 	-53 	10 	22 	-53 	21 	45 	-52
Immunology
Simponi 	191 	214 	-11 	191 	214 	-11
Remicade 	73 	98 	-26 	73 	98 	-26
Neuroscience
Belsomra 	84 	76 	10 	22 	21 	4 	61 	55 	12
Virology
Isentress / Isentress HD 	196 	247 	-21 	76 	94 	-19 	120 	153 	-21
Zepatier 	39 	108 	-63 	15 	39 	-62 	24 	68 	-64
Cardiovascular
Zetia 	137 	156 	-12 	(1) 	6 	-123 	138 	150 	-8
Vytorin 	39 	76 	-49 	2 	3 	-42 	37 	73 	-50
Atozet 	115 	92 	25 	115 	92 	25
Alliance Revenue - Adempas (4) 79 	51 	54 	73 	49 	50 	6 	2 	141
Adempas (5) 57 	53 	8 	57 	53 	8
Diabetes (6)
Januvia 	854 	908 	-6 	413 	471 	-12 	441 	437 	1
Janumet 	490 	533 	-8 	143 	166 	-14 	348 	366 	-5
Women's Health
Implanon / Nexplanon 	132 	183 	-28 	87 	136 	-36 	44 	48 	-7
NuvaRing 	63 	240 	-74 	35 	206 	-83 	28 	34 	-18
Diversified Brands
Singulair 	100 	160 	-38 	4 	8 	-45 	96 	153 	-37
Cozaar / Hyzaar 	98 	109 	-10 	4 	6 	-29 	94 	103 	-9
Arcoxia 	65 	75 	-13 	65 	75 	-13
Nasonex 	49 	72 	-32 	4 	(1) 	* 	45 	73 	-38
Follistim AQ 	44 	63 	-31 	20 	24 	-18 	24 	39 	-39
Other Pharmaceutical (7) 1,103 	1,203 	-8 	385 	369 	4 	720 	837 	-14
ANIMAL HEALTH 	1,101 	1,124 	-2 	342 	335 	2 	759 	789 	-4
Livestock 	648 	671 	-3 	122 	145 	-15 	526 	526
Companion Animals 	453 	453 	220 	190 	16 	233 	263 	-11
Other Revenues (8) 92 	176 	-47 	22 	51 	-57 	70 	125 	-44
* 200% or greater
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $1,418 million and $1,480 million on a global basis for second quarter 2020 and 2019, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of Healthcare Services segment revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Total Vaccines sales were $1,418 million and $2,037 million on a global basis for second quarter 2020 and 2019, respectively.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
SECOND QUARTER 2020
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
8

-- 9 of 12 --

June YTD
2020
June YTD
2019 	% Change
June YTD
2020
June YTD
2019 	% Change
June YTD
2020
June YTD
2019 	% Change
TOTAL SALES (1) $22,929 	$22,575 	2 	$9,771 	$9,748 	$13,158 	$12,828 	3
PHARMACEUTICAL 	20,334 	20,123 	1 	8,984 	9,022 	11,350 	11,101 	2
Oncology
Keytruda 	6,672 	4,903 	36 	3,949 	2,782 	42 	2,722 	2,121 	28
Alliance Revenue - Lynparza (2) 323 	190 	70 	190 	116 	64 	133 	74 	81
Alliance Revenue - Lenvima (2) 279 	171 	63 	188 	104 	81 	91 	67 	36
Emend 	76 	237 	-68 	11 	130 	-92 	65 	107 	-39
Vaccines (3)
Gardasil / Gardasil 9 	1,753 	1,724 	2 	629 	818 	-23 	1,124 	906 	24
ProQuad / M-M-R II / Varivax 	813 	1,171 	-31 	596 	843 	-29 	217 	328 	-34
RotaTeq 	391 	383 	2 	241 	258 	-7 	150 	125 	20
Pneumovax 23 	373 	355 	5 	203 	248 	-18 	170 	107 	60
Vaqta 	88 	105 	-17 	47 	67 	-30 	41 	39 	7
Hospital Acute Care
Bridion 	524 	533 	-2 	250 	248 	1 	274 	285 	-4
Noxafil 	168 	383 	-56 	14 	191 	-93 	154 	192 	-20
Prevymis 	123 	70 	76 	55 	37 	47 	68 	33 	109
Primaxin 	115 	130 	-11 	1 	1 	81 	114 	129 	-12
Invanz 	108 	150 	-28 	6 	31 	-81 	102 	118 	-14
Cancidas 	98 	129 	-23 	1 	4 	-80 	98 	125 	-22
Cubicin 	78 	155 	-50 	25 	64 	-61 	53 	91 	-42
Zerbaxa 	69 	53 	30 	37 	25 	46 	32 	28 	15
Immunology
Simponi 	406 	422 	-4 	406 	422 	-4
Remicade 	160 	221 	-28 	160 	221 	-28
Neuroscience
Belsomra 	163 	143 	14 	49 	45 	9 	114 	98 	16
Virology
Isentress / Isentress HD 	441 	502 	-12 	151 	202 	-25 	290 	300 	-3
Zepatier 	94 	221 	-57 	33 	72 	-55 	62 	149 	-59
Cardiovascular
Zetia 	282 	296 	-5 	(4) 	6 	-161 	285 	290 	-1
Vytorin 	92 	174 	-47 	5 	6 	-14 	86 	167 	-48
Atozet 	238 	186 	28 	238 	186 	28
Alliance Revenue - Adempas (4) 133 	94 	41 	122 	89 	37 	11 	5 	132
Adempas (5) 113 	100 	12 	113 	100 	12
Diabetes (6)
Januvia 	1,628 	1,732 	-6 	768 	855 	-10 	860 	877 	-2
Janumet 	993 	1,063 	-7 	256 	333 	-23 	737 	730 	1
Women's Health
Implanon / Nexplanon 	326 	382 	-15 	237 	285 	-17 	90 	98 	-8
NuvaRing 	126 	459 	-73 	61 	391 	-84 	65 	68 	-5
Diversified Brands
Singulair 	255 	352 	-27 	9 	13 	-31 	246 	338 	-27
Cozaar / Hyzaar 	200 	213 	-6 	12 	10 	13 	189 	202 	-7
Arcoxia 	135 	149 	-9 	135 	149 	-9
Nasonex 	120 	168 	-29 	10 	(2) 	* 	110 	170 	-35
Follistim AQ 	85 	121 	-29 	40 	53 	-25 	45 	67 	-33
Other Pharmaceutical (7) 2,293 	2,283 	792 	697 	14 	1,500 	1,589 	-6
ANIMAL HEALTH 	2,314 	2,149 	8 	726 	628 	16 	1,588 	1,521 	4
Livestock 	1,386 	1,282 	8 	284 	261 	9 	1,102 	1,021 	8
Companion Animals 	928 	867 	7 	442 	367 	20 	486 	500 	-3
Other Revenues (8) 281 	303 	-8 	61 	98 	-38 	220 	206 	7
* 200% or greater
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $2,772 million and $2,882 million on a global basis for June YTD 2020 and 2019, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of Healthcare Services segment revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Total Vaccines sales were $3,574 million and $3,924 million on a global basis for June YTD 2020 and 2019, respectively.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
JUNE YEAR-TO-DATE 2020
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
9

-- 10 of 12 --

% Change
TOTAL PHARMACEUTICAL 	$10,655 	$9,679 	$20,334 	$9,663 	$10,460 	$20,123 	$11,095 	$10,533 	$41,751 	-7
United States (1) 4,714 	4,270 	8,984 	4,215 	4,807 	9,022 	5,180 	4,751 	18,953 	-11
% Pharmaceutical Sales 	44.2% 	44.1% 	44.2% 	43.6% 	46.0% 	44.8% 	46.7% 	45.1% 	45.4%
Europe (2) 2,543 	2,196 	4,739 	2,335 	2,301 	4,636 	2,304 	2,373 	9,314 	-5
% Pharmaceutical Sales 	23.9% 	22.7% 	23.3% 	24.2% 	22.0% 	23.0% 	20.8% 	22.5% 	22.3%
China 	846 	811 	1,657 	725 	745 	1,470 	898 	773 	3,141 	9
% Pharmaceutical Sales 	7.9% 	8.4% 	8.1% 	7.5% 	7.1% 	7.3% 	8.1% 	7.3% 	7.5%
Japan 	789 	847 	1,636 	779 	900 	1,679 	894 	921 	3,494 	-6
% Pharmaceutical Sales 	7.4% 	8.8% 	8.0% 	8.1% 	8.6% 	8.3% 	8.1% 	8.7% 	8.4%
Asia Pacific (other than China and Japan) 	613 	555 	1,168 	642 	606 	1,248 	638 	614 	2,500 	-9
% Pharmaceutical Sales 	5.8% 	5.7% 	5.7% 	6.6% 	5.8% 	6.2% 	5.8% 	5.8% 	6.0%
Eastern Europe/Middle East/Africa 	490 	416 	905 	343 	388 	731 	423 	423 	1,577 	7
% Pharmaceutical Sales 	4.6% 	4.3% 	4.5% 	3.6% 	3.7% 	3.6% 	3.8% 	4.0% 	3.8%
Latin America 	419 	399 	818 	427 	523 	950 	534 	429 	1,914 	-24
% Pharmaceutical Sales 	3.9% 	4.1% 	4.0% 	4.4% 	5.0% 	4.7% 	4.8% 	4.1% 	4.6%
Canada 	212 	160 	372 	177 	179 	356 	211 	216 	783 	-11
% Pharmaceutical Sales 	2.0% 	1.7% 	1.8% 	1.8% 	1.7% 	1.8% 	1.9% 	2.0% 	1.9%
Other (1) 29 	25 	55 	20 	11 	31 	13 	33 	75 	127
% Pharmaceutical Sales 	0.3% 	0.3% 	0.3% 	0.2% 	0.1% 	0.2% 	0.1% 	0.3% 	0.2%
(2) Europe primarily represents all European Union countries and the European Union accession markets.
3Q 	4Q 	Full Year 	2Q
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Alliance revenue related to Adempas attributable to the United States has been reclassified from Other.
1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
2020 	2019
10

-- 11 of 12 --

OTHER (INCOME) EXPENSE, NET
2Q20 	2Q19
June YTD
2020
June YTD
2019
Interest income 	(14)	$ 	(75)	$ 	(39)	$ 	(164)	$
Interest expense 	209 	233 	421 	442
Exchange losses 	24 	27 	78 	128
Income from investments in equity securities, net (1) (551) 	(58) 	(603) 	(32)
Net periodic defined benefit plan (credit) cost other than service cost 	(80) 	(140) 	(170) 	(281)
Other, net 	22 	153 	(5) 	234
Total 	(390)	$ 	140	$ 	(318)	$ 	327	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds
are accounted for on a one quarter lag.
Table 4
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
11

-- 12 of 12 --